Indeed, previous studies have indicated that activated B cells can be used as effective APCs for T-cell sensitisation to tumour antigens.40 IL-10 has been shown to affect directly the function of antigen-presenting cells by inhibiting the expression of major histocompatibility complex and costimulatory molecules,41, 42 which in turn induces immune suppression or tolerance;43 thus; reduced levels into pEEVGmCSF-b7.1-treated mice may also correspond to robust antigen-specific immunity. The gene discussed is CD80; the disease is neoplasm.